Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine
2017 | journal article
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Meyer, Marleen Julia, Tina Seitz, Jürgen Brockmöller, and Mladen Vassilev Tzvetkov. "Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine." PLOS ONE 12, no. 12 (2017): e0189521. https://doi.org/10.1371/journal.pone.0189521.
Documents & Media
Details
- Authors
- Meyer, Marleen Julia ; Seitz, Tina ; Brockmöller, Jürgen ; Tzvetkov, Mladen Vassilev
- Abstract
- Ranitidine (Zantac®) is a H2-receptor antagonist commonly used for the treatment of acid-related gastrointestinal diseases. Ranitidine was reported to be a substrate of the organic cation transporters OCT1 and OCT2. The hepatic transporter OCT1 is highly genetically variable. Twelve major alleles confer partial or complete loss of OCT1 activity. The effects of these polymorphisms are highly substrate-specific and therefore difficult to predict. The renal transporter OCT2 has a common polymorphism, Ala270Ser, which was reported to affect OCT2 activity.
- Issue Date
- 2017
- Journal
- PLOS ONE
- Language
- English
- Sponsor
- Open-Access-Publikationsfonds 2017
